Adrian Schmidt
Overview
Explore the profile of Adrian Schmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bayer J, Brange F, Schmidt A, Wagner T, Rugeramigabo E, Flindt C, et al.
Phys Rev Lett
. 2025 Feb;
134(4):046303.
PMID: 39951596
We experimentally demonstrate the real-time detection and control of correlated charge tunneling in a dynamically driven quantum dot. Specifically, we measure the joint distribution of waiting times between tunneling charges...
2.
Meier-Lienhard R, Suter C, Pabst T, Hitz F, Passweg J, Spertini O, et al.
Swiss Med Wkly
. 2025 Jan;
155():3885.
PMID: 39877935
Introduction: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease, with unique diagnostic challenges and often dismal outcome. There are no widely accepted treatment guidelines available. Lymphoma-like regimens...
3.
Nilius H, Naas S, Studt J, Tsakiris D, Greinacher A, Mendez A, et al.
J Thromb Haemost
. 2024 Nov;
23(2):684-691.
PMID: 39536820
Background: Following the current guidelines, immunoassays for the diagnosis of heparin-induced thrombocytopenia (HIT) are interpreted dichotomously, with test results categorized as either positive or negative. However, the extent to which...
4.
Nilius H, Hamzeh-Cognasse H, Hastings J, Studt J, Tsakiris D, Greinacher A, et al.
Blood Adv
. 2024 Apr;
8(11):2825-2834.
PMID: 38588487
New analytical techniques can assess hundreds of proteins simultaneously with high sensitivity, facilitating the observation of their complex interplay and role in disease mechanisms. We hypothesized that proteomic profiling targeting...
5.
Larsen E, Nilius H, Studt J, Tsakiris D, Greinacher A, Mendez A, et al.
JAMA Netw Open
. 2024 Mar;
7(3):e243786.
PMID: 38530310
Importance: Heparin-induced thrombocytopenia (HIT) is a life-threatening condition that requires urgent diagnostic clarification. However, knowledge of the diagnostic utility of the recommended diagnostic tests is limited in clinical practice. Objective:...
6.
Rovo A, Gavillet M, Drexler B, Keller P, Schneider J, Colucci G, et al.
Front Med (Lausanne)
. 2023 Aug;
10:1200431.
PMID: 37564039
Aim: This study aimed to investigate clinical indications prompting PNH clones' assessment and physician's accessibility of a flow cytometry facility, and also to understand clinical attitudes on the follow-up (FU)...
7.
Burger A, Studt J, Mendez A, Alberio L, Fontana P, Wuillemin W, et al.
Diagnostics (Basel)
. 2023 Jun;
13(12).
PMID: 37371023
A universal calibrator for the determination of all anti-Xa inhibitors would support laboratory processes. We aimed to test the clinical performance of an anti-Xa assay utilizing a universal edoxaban calibrator...
8.
Hammerer-Lercher A, Nilius H, Studt J, Tsakiris D, Greinacher A, Mendez A, et al.
J Thromb Haemost
. 2023 May;
21(9):2559-2568.
PMID: 37247669
Background: Anecdotal reports suggest that the correlation between heparin/platelet factor 4 (PF4) antibody assays for the diagnosis of heparin-induced thrombocytopenia (HIT) is limited. Objectives: To investigate the correlation between widely...
9.
Nilius H, Cuker A, Haug S, Nakas C, Studt J, Tsakiris D, et al.
EClinicalMedicine
. 2022 Dec;
55:101745.
PMID: 36457646
Background: Diagnosing heparin-induced thrombocytopenia (HIT) at the bedside remains challenging, exposing a significant number of patients at risk of delayed diagnosis or overtreatment. We hypothesized that machine-learning algorithms could be...
10.
A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia
Cantoni N, Sommavilla R, Seitz P, Kulenkampff E, Kahn S, Lambert J, et al.
BMC Cancer
. 2022 Nov;
22(1):1192.
PMID: 36402993
Background: The real-world experience of Swiss chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) is largely unknown, in particular with regard to achievement of response per European...